RAVCAR Study

Enrolling Today

Wanted: Participants for a Study of the Immune System

Help us learn how the immune system of healthy individuals and patients with compromised immune systems respond to an inactivated vaccine.
Join our study today.

Understanding the Immune Systems of Healthy Adults and Cancer Patients

This study will help us to better understand how the immune system of healthy adults respond to an FDA-approved inactivated rabies vaccine. This is an inactivated vaccine, so there is no risk of getting rabies infection from the vaccine.

Our bodies produce antibodies when they sense foreign cells. The study will be comparing the antibodies produced after vaccination in healthy volunteers and participants with compromised immune systems from cancer and cancer therapies. 

Let us know if you are interested in joining the study.

For Healthy Volunteers

Eligibility

  • Adult 18 years or older
  • Never received an anti-rabies vaccine
  • Do not have a chronic illness and not currently sick
  • Not pregnant or breast feeding
  • Have not had a reaction to any component of the Imovax Rabies vaccine
     

Participant Requirements

  • Attend two clinic visits for vacinations and pre-vaccination blood draws
  • From home, self-collect seven blood draws over six months with the Tasso OnDemand device

Participant Compensation

  • $100 for the first vaccination
  • $100 for the second vaccination
  • $10 per blood draw
  • Total compensation up to $270

For CAR T Recipients

Eligibility

  • Adult 14 years or older (14-17 years old require permission from a legally authorized guardian)
  • Undergoing or  had CAR T Therapy (eligible after 6 months, relapse-free)
  • Never received an anti-rabies vaccine
  • Not pregnant or breast feeding
  • Have not had a reaction to any component of the Imovax Rabies vaccine

Participant Requirements

  • Attend two clinic visits for vacinations and pre-vaccination blood draws
  • From home, self-collect seven blood draws over six months with the Tasso OnDemand device

Participant Compensation

  • $100 for the first vaccination
  • $100 for the second vaccination
  • $10 per blood draw
  • Total compensation up to $270

Study Details

blood samples icon

People who agree to join the study will be asked to attend up to nine visits over approximately 6 months, although only the two vaccination visits are required to be in-person. 

blood samples icon

Volunteers who agree to participate will be asked to provide nine blood samples throughout the study participation. Two of these samples will be collected during the vaccination visits. Blood draws will also be done at 1, 2 and 4-weeks post each vaccination, and one additional draw six months after the initial vaccinations. Volunteers will be given the option to self-collect blood from home using a Tasso device.

vial and syringe icon

Volunteers will be given two vaccinations scheduled 6-10 weeks apart. The first vaccination is given at the initial clinic vsit. The second vaccination will be scheduled 6-10 weeks after the first vaccination. There will be blood draws prior to each vaccination, and we will still ask you to stay for 15 minutes post-vaccination for observation. The follow-up schedule for the second vaccination will be the same as for the initial visit.

medical record icon

Patients undergoing CAR T treatment only: If you join the study, information about your participation would be made part of your permanent medical record. This information would include a copy of this consent form. If any insurance company, employer, or anyone else authorized to see your medical record were to view it, they would see a copy of this consent form.

Contact Us to Learn More About Our Study

Rina Romano, Lead Coordinator
rromano@fredhutch.org

Learn more about our trial at CT.gov

Hill Group

Joshua Hill, M.D.

Joshua Hill, M.D.

Lead Researcher

Dr. Joshua Hill is a physician who specializes in the treatment of infectious diseases in cancer patients, solid organ transplant patients and others with weakened immune systems. His research includes clinical trials of new medicines to prevent or treat infections in such patients. Dr. Hill’s epidemiological research focuses on infections in immunocompromised hosts, including those receiving new therapies such as CAR T cells.